Research

Hormonal

Tirzepatide 15 mg provides superior HbA1c reduction and bodyweight loss compared to other GLP-1RA-based therapies, including high-dose GLP-1RA and GLP-1RA plus basal insulin fixed-ratio combinations, without increasing the risk of hypoglycemia.

For patients with type 2 diabetes seeking maximum glycemic control and weight loss, tirzepatide 15 mg is the most effective GLP-1RA-based therapy available, outperforming high-dose GLP-1RAs and insulin combinations without increasing hypoglycemia risk.

GoodSupportsHIGH confidence
Tirzepatide 15 mg ranked first in terms of HbA1c reduction compared to other GLP-1RA-based strategies... without increasing the risk of hypoglycaemia... Tirzepatide 15 mg was also the most efficacious on weight lowering, even compared to high-dose GLP-1RA... and GLP-1RA plus SGLT-2i combination
Irene Caruso et al. · EClinicalMedicine · 2023

Why this rating

Network meta-analysis of 40 RCTs with high certainty for the primary outcome, though heterogeneity was high for some secondary outcomes.

Source

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis

Irene Caruso et al. · EClinicalMedicine · 2023

DOI 10.1016/j.eclinm.2023.102181

Meta-analysis · 40 studiesCited 51×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →